Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Elidel

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

A non-steroidal topical cream treatment created for the treatment of chronically relapsing inflammatory skin disease. The non-steroidal topical cream contains 10 mg of pimecrolimus in a whitish cream base of benzyl alcohol, cetyl alcohol, citric acid, mono- and di-glycerides, oleyl alcohol, propylene glycol, sodium cetostearyl sulfate, sodium hydroxide, stearyl alcohol, medium chain triglycerides and water and is used as a second-line therapy for the short and long-term management of the signs and symptoms of mild to moderate atopic dermatitis, where treatment with topical corticosteroids is either inadvisable or not possible, in adults and children.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Acquirer
Primary Office
  • Forum 1
  • Novartis Campus
  • 4056 Basel
  • Switzerland

Elidel Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Elidel‘s full profile, request access.

Request full access to PitchBook

Elidel Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Elidel‘s full profile, request access.

Request full access to PitchBook